Genome-Guided Exploration Of Streptomyces Ambofaciens Secondary Metabolism
Bertrand Aigle,Robert Bunet,Christophe Corre,Amelie Garenaux,Laurence Hotel,Sheng Huang,Luisa Laureti,Sylvie Lautru,Marta Vaz Mendes,Sarka Nezbedova,Hoang Cuong Nguyen,Lijiang Song,Jaroslav Weiser,Gregory Challis,Pierre Leblond,Jean-Luc Pernodet
2011-01-01
Abstract:Members of the Streptomyces genus are among the most prolific microorganisms producing secondary metabolites with wide uses in medicine and in agriculture. Sequencing of the genome of the model Streptomyces, Streptomyces coelicolor, has highlighted an unexpected feature, i.e. that the potential of these organisms to synthesise secondary metabolites has been largely underestimated. They indeed possess many more gene clusters encoding natural product-like biosynthetic pathways than there are known natural products. Similar observations have since been made for other bacterial or fungal genomes. Thus, it has become clear that microbial secondary metabolism has been seriously underestimated and that genome-based approaches are very promising in the search for new bioactive compounds.Here, we present an overview of the secondary metabolite biosynthetic potential of Streptomyces ambofaciens, a species known for decades as producer of the macrolide spiramycin and the pyrrolamide congocidine. Interestingly, genome analysis has revealed that despite of the close phylogenetic relatedness of S. coelicolor and S. ambofaciens, most of its secondary metabolite gene clusters are species-specific.